Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SY-12696
- Development stage
- Unknown
- Lead developer
- Shouyao Holdings
- Modality
- Small Molecules
01
Overview
SY-12696: sourced facts only. name: "SY-12696, a novel and potent MALT1 protease inhibitor, for the treatment of B-cell lymphomas" [DOI:10.1158/1538-7445.am2025-3034]; target: "SY-12696, a novel and potent MALT1 protease inhibitor, for the treatment of B-cell lymphomas" [DOI:10.1158/1538-7445.am2025-3034]; developer: "Shouyao Holdings (Beijing) Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2025-3034]; modality: "SY-12696 was identified as a novel, potent and small molecular MALT1 inhibitor, it showed excellent potency on MALT1 protease activity both in biochemical and in cellular assays with nanomolar IC50s." [DOI:10.1158/1538-7445.am2025-3034]
02
Targets
MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)
Beyond the preview
Go deeper on SY-12696.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SY-12696.